Recombinant activated Factor VII [rFVIIa (NovoSeven®)] is approved for the treatment of bleeding complications with FVIII or FIX inhibitors in patients with congenital FVII deficiency. This evidence concerns the gene F8 and hyperinsulinemic hypoglycemia, familial, 4.